Korsana Biosciences (KRSA) Registration filing summary

Company overview and business model

• Biopharmaceutical business focused on developing treatments for serious diseases; strategy is to build a pipeline for neuropsychiatric diseases.

• After evaluating dozens of opportunities over the past year, prioritized an individualized treatment-resistant depression (TRD) candidate under a non-binding option-to-license agreement.

• Program team is developing an integrated TRD development and commercial strategy; the candidate’s clinical stage, unmet need and commercial potential informed its selection.

Use of proceeds and capital allocation

• No proceeds from the resale of up to 499,998 shares will go to the issuer; sale proceeds accrue to the selling stockholders.

• Selling stockholders pay brokerage commissions and similar sale expenses; registration expenses are paid by the issuer, with estimated issuance and distribution costs of $35,250.

Risk factors and disclosures

• Going-concern ability is subject to substantial doubt; near-term capital raising is needed to maintain operations, with uncertainty around future financial performance and cash flows.

• The TRD candidate remains under evaluation and requires license rights, successful clinical studies, regulatory approval and commercialization; timing, investment and execution are uncertain.

• Nasdaq listing may not be maintained; development and commercialization risks also affect the Tisento investment and potential Akebia milestones and royalties.

• Olinciguat licensing depends on an option holder’s decision and agreement on terms; risks also include IP protection, regulatory compliance, reimbursement, competition and internal controls.

• Ernst & Young’s audit report on FY2024 consolidated financial statements included an explanatory paragraph raising substantial doubt about ability to continue as a going concern.